151 related articles for article (PubMed ID: 19950316)
1. Successful treatment of reactive arthritis with a humanized anti-interleukin-6 receptor antibody, tocilizumab.
Tanaka T; Kuwahara Y; Shima Y; Hirano T; Kawai M; Ogawa M; Arimitsu J; Hagihara K; Narazaki M; Ogata A; Kawase I; Kishimoto T
Arthritis Rheum; 2009 Dec; 61(12):1762-4. PubMed ID: 19950316
[No Abstract] [Full Text] [Related]
2. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study.
Genovese MC; McKay JD; Nasonov EL; Mysler EF; da Silva NA; Alecock E; Woodworth T; Gomez-Reino JJ
Arthritis Rheum; 2008 Oct; 58(10):2968-80. PubMed ID: 18821691
[TBL] [Abstract][Full Text] [Related]
3. Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement.
Woo P; Wilkinson N; Prieur AM; Southwood T; Leone V; Livermore P; Wythe H; Thomson D; Kishimoto T
Arthritis Res Ther; 2005; 7(6):R1281-8. PubMed ID: 16277681
[TBL] [Abstract][Full Text] [Related]
4. [New approaches to pharmacotherapy for rheumatoid arthritis: perspective for use of tocilizumab (monoclonal antibodies to interleukin-6 receptor)].
Nasonov EL
Ter Arkh; 2010; 82(5):64-71. PubMed ID: 20597275
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment with humanised anti-interleukin 6 receptor antibody for multidrug-refractory and anti-tumour necrosis factor-resistant systemic rheumatoid vasculitis.
Sumida K; Ubara Y; Takemoto F; Takaichi K
Clin Exp Rheumatol; 2011; 29(1 Suppl 64):S133. PubMed ID: 21385558
[No Abstract] [Full Text] [Related]
6. Serious herpes zoster in rheumatoid arthritis under anti-interleukin-6 receptor antibody.
Kubandova Z; Mathieu S; Pourtier C; Soubrier M
Joint Bone Spine; 2010 Dec; 77(6):623-4. PubMed ID: 20851657
[No Abstract] [Full Text] [Related]
7. Interleukin-6: a new therapeutic target.
Smolen JS; Maini RN
Arthritis Res Ther; 2006; 8 Suppl 2(Suppl 2):S5. PubMed ID: 16899109
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-6 inhibition--tolerability profile and clinical implications.
Strand V; Yazici Y
Bull NYU Hosp Jt Dis; 2007; 65 Suppl 1():S21-4. PubMed ID: 17708741
[TBL] [Abstract][Full Text] [Related]
9. Treatment of a patient with remitting seronegative, symmetrical synovitis with pitting oedema with a humanized anti-interleukin-6 receptor antibody, tocilizumab.
Tanaka T; Hagihara K; Shima Y; Narazaki M; Ogata A; Kawase I; Kishimoto T
Rheumatology (Oxford); 2010 Apr; 49(4):824-6. PubMed ID: 20008092
[No Abstract] [Full Text] [Related]
10. Use of adalimumab in poststreptococcal reactive arthritis.
Sánchez-Cano D; Callejas-Rubio JL; Ortego-Centeno N
J Clin Rheumatol; 2007 Jun; 13(3):176. PubMed ID: 17551391
[No Abstract] [Full Text] [Related]
11. Tocilizumab, a humanized anti-interleukin-6 receptor antibody, ameliorates joint swelling in established monkey collagen-induced arthritis.
Uchiyama Y; Yorozu K; Hashizume M; Moriya Y; Mihara M
Biol Pharm Bull; 2008 Jun; 31(6):1159-63. PubMed ID: 18520048
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-6 inhibition and clinical efficacy in rheumatoid arthritis treatment--data from randomized clinical trials.
Kavanaugh A
Bull NYU Hosp Jt Dis; 2007; 65 Suppl 1():S16-20. PubMed ID: 17708740
[TBL] [Abstract][Full Text] [Related]
13. Humanized antihuman IL-6 receptor antibody, tocilizumab.
Nishimoto N; Kishimoto T
Handb Exp Pharmacol; 2008; (181):151-60. PubMed ID: 18071945
[TBL] [Abstract][Full Text] [Related]
14. Improvement of HbA1c during treatment with humanised anti-interleukin 6 receptor antibody, tocilizumab.
Ogata A; Morishima A; Hirano T; Hishitani Y; Hagihara K; Shima Y; Narazaki M; Tanaka T
Ann Rheum Dis; 2011 Jun; 70(6):1164-5. PubMed ID: 20980285
[No Abstract] [Full Text] [Related]
15. IL-6 blockers in systemic onset juvenile idiopathic arthritis.
Barone P; Pignataro R; Garozzo MT; Leonardi S
Immunotherapy; 2016; 8(1):79-87. PubMed ID: 26642378
[TBL] [Abstract][Full Text] [Related]
16. Correlation between clinimetric approach and German US7 score in rheumatoid arthritis patients treated with tocilizumab: a pilot study.
Terenzi R; Santoboni G; Bartoloni E; Alunno A; Luccioli F; Gerli R
Clin Exp Rheumatol; 2015; 33(3):445. PubMed ID: 25937244
[No Abstract] [Full Text] [Related]
17. Anti-interleukin-6 receptor antibody therapy in rheumatic diseases.
Nakahara H; Nishimoto N
Endocr Metab Immune Disord Drug Targets; 2006 Dec; 6(4):373-81. PubMed ID: 17214583
[TBL] [Abstract][Full Text] [Related]
18. Response to treatment with tocilizumab of reactive arthritis induced by intravesical bacillus Galmette-Guérin unresponsive to DMARDs.
Kwan K; Bharadwaj S; Inderjeeth C
Int J Rheum Dis; 2012 Aug; 15(4):e73-5. PubMed ID: 22898231
[No Abstract] [Full Text] [Related]
19. Successful use of a humanized anti-interleukin-6 receptor antibody, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis.
Okuda Y; Takasugi K
Arthritis Rheum; 2006 Sep; 54(9):2997-3000. PubMed ID: 16947531
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of anti-interleukin 6 receptor monoclonal antibody (tocilizumab) in Colombian patients with Takayasu arteritis.
Cañas CA; Cañas F; Izquierdo JH; Echeverri AF; Mejía M; Bonilla-Abadía F; Tobón GJ
J Clin Rheumatol; 2014 Apr; 20(3):125-9. PubMed ID: 24662551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
